Currently, the activity of CAR-macrophages in patients is under evaluation in the following two clinical trials (Table 2, source clinicaltrials.org): a phase I clinical trial evaluating the safety of HER2-CAR-Ms in patients affected by 29 different types of tumors, and a second one aimed to investigate the efficacy of human CAR-M against breast cancer organoids with different expression levels of HER2. This evidence concerns the gene ERBB2 and breast carcinoma.